Download the Allegheny Health Network Protected PCI Algorithm to guide decision-making for appropriate use of the Impella® heart pump for Protected PCI.
New data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 sites demonstrates 72% survival with 98% native heart recovery at discharge. The patients were treated with the NCSI protocol, which includes placing the Impella heart pump before revascularization. The study demonstrates the protocol-based approach to … Continue reading “New Data from NCSI Demonstrates 72% Survival with 98% Native Heart Recovery”
Committed to improving outcomes in Cardiogenic Shock and Protected PCI through excellence in education.
Use this patient transfer checklist and documentation when transferring a patient supported with an Impella® device from the “Spoke” hospital to the “Hub” hospital. Completing the patient transfer checklist ensures the best possible outcome for the patient during the transfer process.
A preponderance of evidence from the FDA cVAD Study, Impella Quality Assurance Database and physician-initiated National Cardiogenic Shock Initiative support the recommendation that placing Impella 2.5 or Impella CP pre-PCI improves outcomes.
Use this FDA-approved checklist to guide treatment decisions and determine if the Impella RP is right for your patients. IMP-574
This sheath enables reaccess to the artery for the duration of Impella support with up to an 0.035” guidewire. The additional sheath length may provide improved hemostasis for tissue tracks longer than 6cm.
Adoption of best practices improves survival for patients with Acute Myocardial Infarction and Cardiogenic Shock (AMICS) supported with Impella.
Dr. Michael P. Flaherty’s TCT 2018 presentation on Renal Effects of Impella support during Protected PCI.